CT
Cajal Therapeutics develops novel small molecule and RNA medicines targeting iron-related disorders, including anemias of inflammation and neurodegenerative diseases. The company focuses on restoring systemic and neurological iron homeostasis, which is vital for cellular energy and function. Their lead program is a first-in-class iron mobilizer designed to correct iron transport imbalances.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Cajal Therapeutics develops novel small molecule and RNA medicines targeting iron-related disorders, including anemias of inflammation and neurodegenerative diseases. The company focuses on restoring systemic and neurological iron homeostasis, which is vital for cellular energy and function. Their lead program is a first-in-class iron mobilizer designed to correct iron transport imbalances.